In the first busy week since the August break, six companies and two SPACs entered the public market. VC-backed health and tech fared well, led by 10x Genomics (TXG) and Cloudflare (NET), while ...read more
Satsuma Pharmaceuticals, which is developing a fast-acting dry powder nasal spray for migraines, raised $83 million by offering 5.5 million shares at $15, the midpoint of the $14 to $16 range. The company raised 10% more proceeds than expected by selling an...read more
After a month-long break, the IPO market is picking up with six deals expected to raise $2.2 billion in the week ahead. Three companies are targeting IPO valuations of $3.5 billion or more. SmileDirectClub (SDC) is the week's largest...read more
Satsuma Pharmaceuticals, a clinical-stage biotech developing a therapy for migraines, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more
US IPO Weekly Recap: Tech and life sciences fare well while SmileDirectClub falls flat in 6-IPO week
In the first busy week since the August break, six companies and two SPACs entered the public market. VC-backed health and tech fared well, led by 10x Genomics (TXG) and Cloudflare (NET), while ...read more
Migraine biotech Satsuma Pharmaceuticals prices upsized IPO at $15 midpoint
Satsuma Pharmaceuticals, which is developing a fast-acting dry powder nasal spray for migraines, raised $83 million by offering 5.5 million shares at $15, the midpoint of the $14 to $16 range. The company raised 10% more proceeds than expected by selling an...read more
US IPO Week Ahead: IPO market is all smiles with 6 deals including SmileDirectClub
After a month-long break, the IPO market is picking up with six deals expected to raise $2.2 billion in the week ahead. Three companies are targeting IPO valuations of $3.5 billion or more. SmileDirectClub (SDC) is the week's largest...read more
Migraine biotech Satsuma Pharmaceuticals sets terms for $75 million IPO
Satsuma Pharmaceuticals, a clinical-stage biotech developing a therapy for migraines, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more